公开(公告)号：US10138300B2

公开(公告)日：2018-11-27

申请号：US15640935

申请日：2017-07-03

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Jiann-Shiun Lai ,  Li-Shuang Ai ,  Yan-Da Lai ,  Yen-Yu Wu ,  Yi-San Tsai ,  Yi-Jiue Tsai ,  Juo-Yu Huang ,  Cheng-Chou Yu ,  Chuan-Lung Hsu ,  Chien-Tsun Kuan ,  Szu-Liang Lai ,  Li-Ya Wang

IPC: C07K16/28 ,  C07K16/30 ,  G01N33/74 ,  A61K51/10 ,  A61K31/4439 ,  C07K14/71 ,  C07K16/00 ,  A61K47/68 ,  A61K47/48 ,  A61K39/00

Abstract: The present invention relates to an antibody or antigen-binding fragment thereof that bind human vascular endothelial growth factor receptor 2 (VEGFR-2). The present invention also relates to a method for inhibiting VEGFR-2-mediated signaling in a subject in need, a method for treating diseases and/or disorders caused by or related to VEGFR-2 activity and/or signaling in a subject afflicted with the diseases and disorders, a method for treating tumor in a subject afflicted with the tumor, a method for inhibiting cell proliferation of endothelial cells in a subject in need, and a method for detecting human vascular endothelial growth factor receptor in a sample.

公开(公告)号：US20180186884A1

公开(公告)日：2018-07-05

申请号：US15640935

申请日：2017-07-03

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： JIANN-SHIUN LAI ,  Li-Shuang Ai ,  Yan-Da Lai ,  Yen-Yu Wu ,  Yi-San Tsai ,  Yi-Jiue Tsai ,  Juo-Yu Huang ,  Cheng-Chou Yu ,  Chuan-Lung Hsu ,  Chien-Tsun Kuan ,  Szu-Liang Lai ,  Li-Ya Wang

IPC: C07K16/28 ,  G01N33/74 ,  C07K16/30 ,  A61K51/10 ,  A61K31/4439

CPC classification number: C07K16/2863 ,  A61K31/4439 ,  A61K47/6803 ,  A61K47/6849 ,  A61K51/1027 ,  A61K51/1096 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/71 ,  C07K16/005 ,  C07K16/2818 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/74 ,  G01N2333/71

Abstract: The present invention relates to an antibody or antigen-binding fragment thereof that bind human vascular endothelial growth factor receptor 2 (VEGFR-2). The present invention also relates to a method for inhibiting VEGFR-2-mediated signaling in a subject in need, a method for treating diseases and/or disorders caused by or related to VEGFR-2 activity and/or signaling in a subject afflicted with the diseases and disorders, a method for treating tumor in a subject afflicted with the tumor, a method for inhibiting cell proliferation of endothelial cells in a subject in need, and a method for detecting human vascular endothelial growth factor receptor in a sample.

公开(公告)号：US12187806B2

公开(公告)日：2025-01-07

申请号：US17686666

申请日：2022-03-04

Applicant: Development Center for Biotechnology

Inventor： Chun-Chung Lee ,  Yu-Hsun Lo ,  Chu-Bin Liao ,  Chen-Jei Hong ,  Sih-Yu Chen ,  Yen-Yu Wu ,  Szu-Liang Lai ,  Chih-Yung Hu ,  Wen-Bin Ke ,  Ya-Ting Juan ,  Kao-Jean Huang

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  A61K39/00

Abstract: The present invention relates to a novel antibody, an antigen-binding fragment thereof and the uses of the antibody and fragment, wherein the antibody and the fragment comprise specific complementarity-determining regions (CDRs) and/or specifically bind to human CD73 at specific epitopes.

公开(公告)号：US20160130336A1

公开(公告)日：2016-05-12

申请号：US14895297

申请日：2014-12-29

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY ,  DCB-USA LLC

Inventor： Jiann-Shiun Lai ,  Yan-Da Lai ,  Yen-Yu Wu ,  Yi-Jiue Tsai ,  Yu-Ying Lin

IPC: C07K16/22

CPC classification number: C07K16/22 ,  A61K2039/505 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

Abstract: An anti-VEGF antibody, or a binding fragment thereof, includes a heavy-chain variable region that comprises: (1) a CDRH1 sequence selected from SEQ ID NO: 17, 20, 23, 26, 29, 32, 35, or 38), (2) a CDRH2 sequence selected from SEQ ID NO:18, 21, 24, 27, 30, 33, 36, or 39, and (3) a CDRH3 sequence selected from SEQ ID NO:19, 22, 25, 28, 31, 34, 37, or 40; and a light-chain variable region that comprises: (1) a CDRL1 sequence selected from SEQ ID NO: 41, 44, 47, 50, 53, 56, 59, or 62, (2) a CDRL2 sequence selected from SEQ ID NO: 42, 45, 48, 51, 54, 57, 60, or 63, and (3) a CDRL3 sequence selected from SEQ ID NO: 43, 46, 49, 52, 55, 58, 61, or 64. A method for treating or preventing a VEGF-related disorder, e.g., diabetic retinopathy, age-related macular degeneration, or cancer, uses the antibodies.

Abstract translation: 抗VEGF抗体或其结合片段包括重链可变区，其包含：（1）选自SEQ ID NO：17,20,23,26,29,32,35或38的CDRH1序列 ），（2）选自SEQ ID NO：18,21,24,27,30,33,36或39的CDRH2序列，和（3）选自SEQ ID NO：19,22,25， 28，31，34，37或40; 和轻链可变区，其包含：（1）选自SEQ ID NO：41,44,47,50,53,56,59或62的CDRL1序列，（2）选自SEQ ID NO： ：42,45,48,51,54,57,60或63，和（3）选自SEQ ID NO：43,46,49,52,55,58,61或64的CDRL3序列。一种方法 用于治疗或预防VEGF相关病症，例如糖尿病性视网膜病变，年龄相关性黄斑变性或癌症，使用抗体。